These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 33326735

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Loss of Blood-Brain Barrier Integrity in an In Vitro Model Subjected to Intermittent Hypoxia: Is Reversion Possible with a HIF-1α Pathway Inhibitor?
    Voirin AC, Chatard M, Briançon-Marjollet A, Pepin JL, Perek N, Roche F.
    Int J Mol Sci; 2023 Mar 06; 24(5):. PubMed ID: 36902491
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Nrf2 signaling increases expression of ATP-binding cassette subfamily C mRNA transcripts at the blood-brain barrier following hypoxia-reoxygenation stress.
    Ibbotson K, Yell J, Ronaldson PT.
    Fluids Barriers CNS; 2017 Mar 16; 14(1):6. PubMed ID: 28298215
    [Abstract] [Full Text] [Related]

  • 7. Hypoxia increases expression of selected blood-brain barrier transporters GLUT-1, P-gp, SLC7A5 and TFRC, while maintaining barrier integrity, in brain capillary endothelial monolayers.
    Ozgür B, Helms HCC, Tornabene E, Brodin B.
    Fluids Barriers CNS; 2022 Jan 04; 19(1):1. PubMed ID: 34983574
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Altered Nrf2 signaling mediates hypoglycemia-induced blood-brain barrier endothelial dysfunction in vitro.
    Sajja RK, Green KN, Cucullo L.
    PLoS One; 2015 Jan 04; 10(3):e0122358. PubMed ID: 25807533
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Re-evaluation of the hCMEC/D3 based in vitro BBB model for ABC transporter studies.
    Balzer V, Poc P, Puris E, Martin S, Aliasgari M, Auriola S, Fricker G.
    Eur J Pharm Biopharm; 2022 Apr 04; 173():12-21. PubMed ID: 35227855
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Hypoxic Stress Induced by Hydralazine Leads to a Loss of Blood-Brain Barrier Integrity and an Increase in Efflux Transporter Activity.
    Chatard M, Puech C, Roche F, Perek N.
    PLoS One; 2016 Apr 04; 11(6):e0158010. PubMed ID: 27337093
    [Abstract] [Full Text] [Related]

  • 20. P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson's disease candidate drug FLZ across the physiological and PD pathological in vitro BBB models.
    Liu Q, Hou J, Chen X, Liu G, Zhang D, Sun H, Zhang J.
    PLoS One; 2014 Apr 04; 9(7):e102442. PubMed ID: 25036090
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.